SG11201405755QA - Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate - Google Patents

Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate

Info

Publication number
SG11201405755QA
SG11201405755QA SG11201405755QA SG11201405755QA SG11201405755QA SG 11201405755Q A SG11201405755Q A SG 11201405755QA SG 11201405755Q A SG11201405755Q A SG 11201405755QA SG 11201405755Q A SG11201405755Q A SG 11201405755QA SG 11201405755Q A SG11201405755Q A SG 11201405755QA
Authority
SG
Singapore
Prior art keywords
laquinimod
treatment
combination
multiple sclerosis
dimethyl fumarate
Prior art date
Application number
SG11201405755QA
Other languages
English (en)
Inventor
Joel Flaxman Kaye
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of SG11201405755QA publication Critical patent/SG11201405755QA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Exchange Systems With Centralized Control (AREA)
  • Liquid Crystal Substances (AREA)
SG11201405755QA 2012-03-27 2013-03-26 Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate SG11201405755QA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261616337P 2012-03-27 2012-03-27
US13/800,047 US20130259856A1 (en) 2012-03-27 2013-03-13 Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate
PCT/US2013/033885 WO2013148690A1 (en) 2012-03-27 2013-03-26 Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate

Publications (1)

Publication Number Publication Date
SG11201405755QA true SG11201405755QA (en) 2014-10-30

Family

ID=49235339

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201405755QA SG11201405755QA (en) 2012-03-27 2013-03-26 Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate
SG10201607976WA SG10201607976WA (en) 2012-03-27 2013-03-26 Treatment Of Multiple Sclerosis With Combination of Laquinimod And Dimethyl Fumarate

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201607976WA SG10201607976WA (en) 2012-03-27 2013-03-26 Treatment Of Multiple Sclerosis With Combination of Laquinimod And Dimethyl Fumarate

Country Status (17)

Country Link
US (6) US20130259856A1 (enExample)
EP (1) EP2830623A4 (enExample)
JP (2) JP2015512406A (enExample)
KR (1) KR20150003765A (enExample)
CN (2) CN104470520A (enExample)
AR (1) AR090491A1 (enExample)
AU (2) AU2013239850A1 (enExample)
CA (1) CA2868259A1 (enExample)
EA (1) EA201491773A1 (enExample)
HK (1) HK1205941A1 (enExample)
IL (1) IL234687A0 (enExample)
MX (1) MX2014011616A (enExample)
SG (2) SG11201405755QA (enExample)
TW (1) TW201343164A (enExample)
UY (1) UY34720A (enExample)
WO (1) WO2013148690A1 (enExample)
ZA (1) ZA201407722B (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2334378B1 (en) 2008-08-19 2014-04-09 XenoPort, Inc. Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use
HK1199820A1 (en) 2011-10-12 2015-07-24 Teva Pharmaceutical Industries Ltd. Treatment of multiple sclerosis with combination of laquinimod and fingolimod
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
US9504679B2 (en) 2011-12-19 2016-11-29 Bjoern Colin Kahrs Pharmaceutical compositions comprising glitazones and Nrf2 activators
AR089862A1 (es) 2012-02-03 2014-09-24 Teva Pharma USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA
EP2744498A4 (en) 2012-02-16 2014-12-03 Teva Pharma N-ETHYL-N-PHENYL-1,2-DIHYDRO-4,5-DI-HYDROXY-1-METHYL-2-OXO-3-CHINOLINE CARBOXAMIDE AND THE PREPARATION AND USE THEREOF
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
EP2692343A1 (en) * 2012-08-03 2014-02-05 Forward Pharma A/S Combination therapy for treatment of multiple sclerosis
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
AU2013305684B2 (en) 2012-08-22 2016-11-24 Xenoport, Inc. Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof
JP2015527372A (ja) 2012-08-22 2015-09-17 ゼノポート，インコーポレイティド 副作用を低減させるモノメチルフマレートおよびそのプロドラッグの投与方法
HK1215210A1 (zh) 2012-11-07 2016-08-19 Teva Pharmaceutical Industries Ltd. 拉喹莫德胺盐
CA2901849A1 (en) 2013-03-14 2014-09-25 Teva Pharmaceutical Industries Ltd. Crystals of laquinimod sodium and improved process for the manufacture thereof
WO2014160633A1 (en) 2013-03-24 2014-10-02 Xenoport, Inc. Pharmaceutical compositions of dimethyl fumarate
WO2014197860A1 (en) 2013-06-07 2014-12-11 Xenoport, Inc. Method of making monomethyl fumarate
US9421182B2 (en) 2013-06-21 2016-08-23 Xenoport, Inc. Cocrystals of dimethyl fumarate
EP3041467A1 (en) 2013-09-06 2016-07-13 XenoPort, Inc. Crystalline forms of (n,n-diethylcarbamoyl)methyl methyl (2e)but-2-ene-1,4-dioate, methods of synthesis and use
US9326947B1 (en) 2014-02-28 2016-05-03 Banner Life Sciences Llc Controlled release fumarate esters
WO2015130998A1 (en) 2014-02-28 2015-09-03 Banner Life Sciences Llc Controlled release enteric soft capsules of fumarate esters
US10098863B2 (en) 2014-02-28 2018-10-16 Banner Life Sciences Llc Fumarate esters
US9636318B2 (en) 2015-08-31 2017-05-02 Banner Life Sciences Llc Fumarate ester dosage forms
US9999672B2 (en) 2014-03-24 2018-06-19 Xenoport, Inc. Pharmaceutical compositions of fumaric acid esters
SG11201608674UA (en) 2014-04-29 2016-11-29 Teva Pharma Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status
MA41139A (fr) 2014-12-11 2017-10-17 Actelion Pharmaceuticals Ltd Combinaison pharmaceutique comportant un agoniste sélectif du récepteur sip1
UA122064C2 (uk) 2014-12-11 2020-09-10 Актеліон Фармасьютікалз Лтд Схема дозування для селективного агоніста рецептора s1p1
GB2540163A (en) * 2015-07-07 2017-01-11 Univ London Queen Mary Combination therapy for treating multiple sclerosis
WO2017120355A1 (en) * 2016-01-06 2017-07-13 Teva Pharmaceutical Industries Ltd. Dihydroquinolines and uses thereof
US11903918B2 (en) 2020-01-10 2024-02-20 Banner Life Sciences Llc Fumarate ester dosage forms with enhanced gastrointestinal tolerability
US12483171B2 (en) 2023-12-18 2025-11-25 Abb Schweiz Ag Plug and play solid state controller for high efficiency motors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6077851A (en) 1998-04-27 2000-06-20 Active Biotech Ab Quinoline derivatives
SE0400235D0 (sv) 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
WO2007006308A1 (en) * 2005-07-07 2007-01-18 Aditech Pharma Ab Novel glucopyranose esters and glucofuranose esters of alkyl- fu marates and their pharmaceutical use
EP2687512A1 (en) 2005-10-19 2014-01-22 Teva Pharmaceutical Industries Ltd. Crystals of Laquinimod Sodium, and Process for the Manufacture Thereof
US7989473B2 (en) * 2006-06-12 2011-08-02 Teva Pharmaceutical Industries, Ltd. Stable laquinimod preparations
LT2653873T (lt) * 2007-02-08 2022-10-10 Biogen Ma Inc. Kompozicijos ir naudojimas, skirti išsėtinei sklerozei gydyti
US20100130607A1 (en) * 2007-02-08 2010-05-27 Ralf Gold Neuroprotection in demyelinating diseases
US20100260755A1 (en) * 2009-04-09 2010-10-14 Medicinova, Inc. Ibudilast and immunomodulators combination
EP3466420A1 (en) * 2009-04-29 2019-04-10 Biogen MA Inc. Dimethyl fumarate for the treatment of friedreich ataxia
WO2010147665A1 (en) * 2009-06-19 2010-12-23 Teva Pharmaceutical Industries Ltd. Treatment of multiple sclerosis with laquinimod
DK2533634T3 (en) * 2010-02-12 2016-01-25 Biogen Ma Inc NEURO PROTECTIVE demyelinating diseases
CA2825009A1 (en) * 2011-01-25 2012-08-02 Novartis Ag Systems and methods for medical use of motion imaging and capture
TW201347762A (zh) * 2012-05-02 2013-12-01 Teva Pharma 高劑量拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）於治療多發性硬化症之用途

Also Published As

Publication number Publication date
TW201343164A (zh) 2013-11-01
CN104470520A (zh) 2015-03-25
HK1205941A1 (en) 2015-12-31
US20150119420A1 (en) 2015-04-30
AU2013239850A1 (en) 2014-11-06
AR090491A1 (es) 2014-11-19
US20170224675A1 (en) 2017-08-10
UY34720A (es) 2013-10-31
MX2014011616A (es) 2014-10-17
KR20150003765A (ko) 2015-01-09
SG10201607976WA (en) 2016-11-29
US20170319570A1 (en) 2017-11-09
IL234687A0 (en) 2014-11-30
US20180050031A1 (en) 2018-02-22
CA2868259A1 (en) 2013-10-03
US20130259856A1 (en) 2013-10-03
ZA201407722B (en) 2016-06-29
EA201491773A1 (ru) 2015-02-27
JP2015512406A (ja) 2015-04-27
JP2017200927A (ja) 2017-11-09
AU2018200065A1 (en) 2018-02-01
CN105853422A (zh) 2016-08-17
US20160000774A1 (en) 2016-01-07
EP2830623A1 (en) 2015-02-04
EP2830623A4 (en) 2015-09-02
WO2013148690A1 (en) 2013-10-03

Similar Documents

Publication Publication Date Title
ZA201407722B (en) Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate
ZA201403378B (en) Treatment of multiple sclerosis with combination of laquinimod and fingolimod
ZA201502503B (en) Hppd variants and methods of use
IL251397A0 (en) Treatment of multiple sclerosis by administering a combination of laquinimod and glatiramer acetate
ZA201401217B (en) Treatment of multiple sclerosis with combination of laquinimod and interferon-beta
IL252547A0 (en) Treatment of multiple sclerosis using laquinimod
EP2870138A4 (en) N-SUBSTITUTED BENZAMIDES AND METHOD OF USE THEREOF
SG11201403980VA (en) Anesthetic compounds and related methods of use
ZA201405858B (en) Recombinant microorganisms and methods of use thereof
ZA201408055B (en) Compositions and methods for the treatment of local pain
IL240014A0 (en) Treatment of multiple sclerosis using laquinimod
GB201103293D0 (en) Treatment and prevention of malaria
ZA201504405B (en) 6-chloro-3-(phenyl-d5)-inden-1-one and use thereof
IL236230A0 (en) Treatment of multiple sclerosis by a combination of laquinimod and pamperidine
EP2670438A4 (en) SELECTION AND TREATMENT OF PATIENTS
ZA201408062B (en) Compositions and methods for the treatment of multiple sclerosis
ZA201405829B (en) Cleaning arrangement and method of use
IL243486A0 (en) Treatment of multiple sclerosis using a combination of laquinimod and flupirtine
ZA201408128B (en) Etract of greyia radlkoferi and use thereof
IL246078A0 (en) Treatment of multiple sclerosis by a combination of laquinimod and triflunomide
HUE048382T2 (hu) 6-klór-3-(fenil-d5)-inden-1-on és alkalmazása